High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
Bruce J. Giantonio(Northwestern University), Al B. Benson(Northwestern University), Neal J. Meropol(Flatiron Health (United States)), Paul J. Catalano(Computational Physics (United States)), Edith P. Mitchell(Thomas Jefferson University Hospital), Steven R. Alberts(North Central Cancer Treatment Group), Morton A. Schwartz, P J O’Dwyer(University College Cork)
Cited by 344
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|1.4k
Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
|New England Journal of Medicine|2012|1.1k